115 results about "Acute gout" patented technology

The invention relates to application of a stilbene derivative and pharmaceutically acceptable salts thereof to preparation of medicines or health-care products for preventing and/or treating hyperuricemia, and acute gout, chronic gout, gouty arthritis, gout attack, uric acid nephrolithiasis and gouty nephropathy caused by the hyperuricemia. The stilbene derivative is used as an active component for preparing the medicines for treating the hyperuricemia, can reduce the concentration of uric acid in blood, has a significant effect on treatment of the hyperuricemia, does not have toxic or side effects and has good safety.

The invention discloses novel medicinal application of coreopsis tinctoria, and particularly relates to application of coreopsis tinctoria extract to preparing medicines for treating hyperuricemia. The novel medicinal application has the advantages that effects of treating the hyperuricemia can be realized by the coreopsis tinctoria extract, the concentration of uric acid in blood can be effectively reduced, and excellent curative effects can be realized for metabolic diseases such as acute gout, chronic gout, gouty arthritis, gout flare, uric acid renal lithiasis and gouty nephropathy which are relevant to the hyperuricemia.

The present invention provides a solid medicine combination, which comprises 2 - (3 - cyano -4 - butyl rubber oxygen phenyl) -4 - methyl -5 - thiazole formic acid as active ingredients; and polyethylene glycol. In addition, the present invention is combined with one or a plurality of medicine excipients. The present is used for the curing of gout and hyperuricemia and reducing the outbreak of acute gout.

The invention relates to the field of organic synthesis and pharmaceutical chemistry, and specifically relates to a cleistanone derivative, a preparation method and an application of the cleistanone derivative in preparing a drug for resisting acute gout. The invention synthesizes a novel cleistanone derivative, and discloses a preparation method thereof. Pharmacology experiments show that the cleistanone derivative provided by the invention has the effects of resisting the acute gout and has the value of developing the drug for resisting the acute gout.

The invention provides a medicine for treating gout, in particular relates to a particle for eliminating turbidity and treating arthralgia, which is prepared from rhizoma smilacis glabrae, coix seed, red peony root and caulis lonicerae. The particle is used for clinically treating acute gout, does not have side effects caused by treatment of Western medicines, has obvious effects on resisting inflammation and relieving pain, and has strong medical effect and lasting action. The short-term treatment effect of the particle is equivalent to the short-term treatment effect of Western medicine colchicine, and the long-term treatment effect of the particle is better than the long-term treatment effect of the colchicine.

The invention relates to a humanized anti-human-interleukin-1[belta] monoclonal antibody, preparation thereof and applications thereof. The light chain of the monoclonal antibody has an amino acid sequence shown as SEQIDNO:1, and the heavy chain of the monoclonal antibody has an amino acid sequence shown as SEQIDNO:2. The antibody can be used for treating various diseases such as acute gout, rheumatoid arthritis, II-type diabetes, non-infectious uveitis, etc. which are related to interleukin 1[belta] pathological functions.

The invention relates to use of combination of potassium and magnesium for preparing a medicine for preventing or treating gout, wherein the potassium and the magnesium are in pharmaceutically acceptable salt form. The scheme of the invention can efficiently prevent or treat the acute gout with little toxic and side effects; therefore, the invention provides a new selection for preventing or treating the gout.

The invention provides novel application of Houttuynoid C in the medical science, in particular application of Houttuynoid C for preparing a medicine for treating acute gout. The experimental research result shows that Houttuynoid C has the effect of protecting an acute gout model of human vascular endothelial cell damage caused by urate and can inhibit expression of ICAM-1, therefore, Houttuynoid C can be used for preparing the medicine for treating acute gouty inflammation. The application of Houttuynoid C for preparing the medicine for treating acute gout is disclosed for the first time; because the skeleton type belongs to a brand new skeleton type and the activity of Houttuynoid C for preventing and treating acute gout is strong unexpectedly, the possibility that other compounds give any inspiration does not exist; Houttuynoid C has outstanding substantive characteristics; and simultaneously, Houttuynoid C has obvious progress for preventing and treating acute gout.

The invention provides an application of salidroside in preparation of a medicine for resisting gouty arthritis, and particularly relates to prevention and curing functions of salidroside on acute gouty arthritis. The salidroside has the benefits as follows: the salidroside has prevention and curing functions on gouty arthritis, especially acute gouty arthritis. The animal experiment proves that sodium urate induced acute gouty arthritis can really be relieved by the salidroside. Therefore, when the salidroside is applied to preparation of the medicine for resisting gouty arthritis, one natural or natural-like medicine can be provided for treatment of gouty arthritis, and adverse effects caused by the medicine for treating gouty arthritis are reduced.

The invention relates to the fields of organic synthesis and pharmaceutical chemistry, in particular to O-(piperazinyl) ethyl derivative of cleistanone, and a preparation method and the application of the O-(piperazinyl) ethyl derivative to the preparation of medicine for resisting acute gout. The invention compounds new O-(piperazinyl) ethyl derivative, and discloses a preparation method thereof. Pharmacology experiments show that the O-(piperazinyl) ethyl derivative has the effect of resisting acute gout, and has the value of developing medicine for resisting acute gout.

The invention relates to a traditional Chinese medicine and application of its extracted composition in treating gout, and particularly relates to a traditional Chinese medicine. The traditional Chinese medicine is characterized by being prepared from, by weight, 0.5-2 parts of radix aconiti lateralis prepared, 2-8 parts of jasmine, 2-8 parts of endive root, 1-5 parts of szechwan Chinaberry fruit, 1-5 parts of semen plantaginis, and 1-6 parts of pueraria. The function of traditional Chinese medicine and its extractive in treating hyperuricemia and acute gout arthritis is better than allopurinol and colchicine; moreover, the toxic and side effects are low.

The invention relates to the fields of organic synthesis and medicinal chemistry, and in particular relates to a composition, a preparation method and application of the composition in preparing a drug for resisting acute gout. The invention discloses a composition and a preparation method thereof. Based upon pharmacological experiments, the composition disclosed by the invention has an effect on resisting the acute gout, so that the composition has the value of developing the drug for resisting the acute gout.

The invention provides a new use of Aphanamixoid A in medical science, and particularly relates to application of preparation of the Aphanamixoid A in medicines curing acute gout. Experiment research indicates that the Aphanamixoid A has protective effect on an acute gout model in which urate causes damage of vascular endothelial cell, and restrains expression of intercellular cell adhesion molecule (ICAM)-1. Therefore, the Aphanamixoid A can be used for preparation of the medicines curing acute gout inflammation. Use of the Aphanamixoid A in preparation of the medicines curing the acute gout is made public for the first time. Due to the fact that skeleton type belongs to completely novel skeleton type, and the Aphanamixoi A has an unexpectedly high activity of preventing and curing the acute gout, probability of other compounds giving any revelation for the Aphanamixoi A does not exist, outstanding substantive features are provided, meanwhile, prominent improvement is evidently possessed in preventing and curing the acute gout.

The invention discloses a health-care medicinal wine for treating gout. The health-care medicinal wine is prepared from the following components of carapax et plastrum testudinis, rhizoma et radix notopterygii, rhizoma pinelliae preparata, earthworm, myrrh, radix rehmanniae, radix ophiopogonis, herba asari, radix rehmanniae praeparata, folium perillae, radix dipsaci, lucid ganoderma, rhizoma cibotii, semen ginkgo, radix ginseng cruda, radix platycodonis, rhizoma polygonati odorati, radix angelicae sinensis, radix aucklandiae, cinnabaris, cortex eucommiae, ossa draconis, lignum sappan, rhizomapolygonati, flos caryophylli, fructus amomi, liquorice root, rhizoma atractylodis macrocephalae, cortex phellodendri chinensis, radix notoginseng, lotus nut, radix asparagi, radix astragali seu hedysari, radix saposhnikoviae, flos carthami, sweet osmanthus flower, rhizoma gastrodiae, poria cocos, zaocys dhumnade, radix angelicae pubescentis, rhizoma chuanxiong, fructus lycii, ramulus mori, flos chrysanthemi, folium piper wallichii, radix saussureae lappae, bulbus fritillariae cirrhosae, herba speranskiae tuberculatae, black fructus psoraleae, radix aconiti lateralis preparata and ricinus communis. The health-care medicinal wine has the advantages that the rare crude drugs are selected, and the traditional technology is used for processing; the convenience in use is realized, and the health-care medicine is used for treating the gouty arthritis, muscle and bone aching and sprain, gout and scapulohumeral periarthritis of the whole body; the health-care medicinal wine is suitable for relaxing channels and collaterals, diminishing inflammation and relieving pain, treating acute gout, and preventing related joint injury and kidney and liver injury due to precipitation of urate.

The invention provides a new application of Orientin in medicine, specifically the application of Orientin in the preparation of medicine for treating acute gout. Experimental research results show that Orientin has a protective effect on the acute gout model of human vascular endothelial cell damage caused by urate, and inhibits the expression of ICAM‑1. Therefore, Orientin can be used to prepare a drug for treating acute gout inflammation. The use of Orientin involved in the present invention in the preparation of medicines for the treatment of acute gout is disclosed for the first time. Since the skeleton type belongs to a new skeleton type, and its preventive and treatment activity for acute gout is so strong that it is unexpected, there is no possibility of giving any inspiration from other compounds , has outstanding substantive features, and it is obviously a significant progress in the prevention and treatment of acute gout.

A homeopathic topical gel for transdermal delivery of colchicine formulations is disclosed. The colchicine formulations are effective in the treatment of constantly recurring acute gout flares. The homeopathic topical gels deliver an attenuated colchicine which has been produced using a degree of succussion and a level of water purity in excess of the guidelines for manufacturing homeopathic medicines set forth in the Homeopathic Pharmacopoeia of the United States.

The invention discloses a pharmaceutical composition for treating acute gout and its extraction method, wherein the composition composes active constituents extracted from the following medicinal materials, corktree bark, atractylodes rhizome, achyranthes and cyathula root, coix seed, poria cocos, and honey-suckle stem, alkaloids, volatile oil, saponin, organic acid, flavone and carbohydrate by a finite proportion.

The invention provides a new application of syringin in medical science, in particular to application of syringin in the preparation of a medicine for treating acute gout. Syringin is extracted and separated from acanthopanax roots and other plants, and the extraction method comprises the following steps of: refluxing and extracting dry acanthopanax root powder with ethanol, recovering the ethanol, adding water to the concentrated solution, stirring to obtain a mixed suspension, extracting with petroleum ether, extracting the water layer with acetic ether, merging the acetic ether layer, concentrating under reduced pressure to obtain an extract, separating by using a silica gel column, carrying out gradient elution by using chloroform and methanol in sequence to obtain a coarse crystal, and recrystallizing with methanol to obtain a syringin crystal. Experimental researches show that syringin can protect an acute gout model due to human vascuoar endothelial cell damages caused by urate and inhibit the expression of ICAM-1 (Intercellular Adhesion Molecule-1); thus, syringin can be used for preparing a medicine for treating acute gout.

The invention relates to traditional Chinese medicine composition for treating gout. The traditional Chinese medicine composition is prepared from raw materials in parts by weight as follows: 2-10 parts of amur corktree bark, 5-8 parts of swordlike atractylodes rhizomes, 7-20 parts of glabrous greenbrier rhizomes, 4-9 parts of plantain herbs, 3-10 parts of oriental waterplantain rhizomes, 5-12 parts of dandelion, 6-10 parts of honeysuckle, 3-14 parts of indigowoad roots, 10-20 parts of scandent schefflera stems and leaves, 4-20 parts of weeping forsythiae capsule, 6-8 parts of dwarf lilyturf tubers, 3-6 parts of cape jasmines, 2-7 parts of chicken's gizzard-membranes, 8-10 parts of cherokee rose fruits, 2-5 parts of fragrant solomonseal rhizomes, 7-10 parts of tortoise plastron, 3-6 parts of sharpleaf galangal fruits, 1-8 parts of clematis roots, 4-7 parts of cassia seeds, 3-6 parts of herbs of spicate clerodendranthus, 4-9 parts of fineleaf schizonepeta herbs and 10-20 parts of snake gallbladder. Granules prepared with a preparation method are convenient to take, taste good, take effect quickly and have a certain treatment effect on obesity complicated with acute gouty arthritis, diabetes, hypertension, hyperlipemia and the like.

The invention relates to the fields of organic synthesis and pharmaceutical chemistry, and specifically relates to a cleistanone derivative, a preparation method thereof, and an application of the cleistanone derivative in the preparation of drugs for treating acute gout. A novel cleistanone derivative is synthesized, and a preparation method thereof is disclosed. The pharmacological experiments show that the cleistanone derivative has an effect on resisting acute gout and can be used to develop drugs for treating acute gout.

The invention provides new application of Gypensapogenin B in medicine, namely application of Gypensapogenin B in preparing a medicine for treating acute gout. Experiment research results indicate that t Gypensapogenin B has the protective effect on acute gout models with human blood vessel endothelium cells damage cuased by urate, and restrains ICAM (intercellular adhesion molecule)-1 expression, so that Gypensapogenin B can be used for preparing the medicine for treating acute gout. The application of Gypensapogenin B in preparing the medicine for treating acute gout, which is provided by the invention, is disclosed for the first time. The skeleton type belongs to brand-new skeleton type, and the prevention activity of Gypensapogenin B to acute gout is extremely strong, so that no possibility for providing any prompt by other compounds exists. Gypensapogenin B has outstanding actual characteristics. Meanwhile, Gypensapogenin B has outstanding progress when being used for preventing and curing acute gout.

The invention provides a new application of Chukrasone B in medical science, and particularly relates to an application of the Chukrasone B in the preparation of medicines for treating acute gout. Experimental research results show that the Chukrasone B has a protection effect on the human vascular endothelial cell damaged acute grout caused by monosodium urate and can be used for inhibiting the expression of ICAM-1 (Intercellular Cell Adhesion Molecule-1), therefore, the Chukrasone B can be used for the preparation of the medicines for treating acute gout inflammation. The application of the Chukrasone B in the preparation of the medicines for treating the acute gout is disclosed by the invention for the first time. As the skeleton type of the Chukrasone B belongs to a bran-new skeleton type and the Chukrasone B has unexpected strong activity on the prevention and treatment of the rheumatoid rhinitis, the possibility that other compounds provide revelation does not exist. The Chukrasone B has prominently substantial characteristics and meanwhile has remarkably progressive significance when being used for preventing and treating the acute gout.

The invention relates to the fields of organic synthesis and medicinal chemistry, in particular to a composition 38083001030527, a preparation method of the composition 38083001030527, and application of the composition 38083001030527 to a drug for resisting acute gout, and discloses the composition 38083001030527 and the preparation method. Pharmacological experiments show that the composition 38083001030527 plays a role in resisting acute gout, thereby having a high value on development of the drug for resisting acute gout.

The invention discloses traditional Chinese medicine external lotion for curing acute gouty arthritis. The traditional Chinese medicine considers that acute gout is caused by the fact that a patient overeats and is fat, and the spleen and the stomach are hurt; as a result, water-dampness transportation and transformation are disordered, and wet heat is generated in the body and flows to joints to obstruct qi-blood circulation and cause stasis and fire-transmission; thus, the clinical manifestations such as red and swollen joints, heat pain, burning sensation and movement disturbance are generated. The traditional Chinese medicine external lotion is prepared from humifuse euphorbia herb, plebeian sage root, all grass of capitatestigma willow weed, eragrostis poaeoides, caragana rosea, amphicome, lindera thomsonii, salvinia nutans, panax notoginseng, callicarpa longissima and stem and leaf of wild spikenard. By clinical experiment, the total effective rate is 94 percent, and the curative effect is remarkable.